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Abstract
Background: Asthma and chronic obstructive pulmonary disease (COPD) are common chronic inflammatory
respiratory diseases, which impose a substantial burden on healthcare systems and society. Fixed-dose
combinations (FDCs) of inhaled corticosteroids (ICS) and long-acting β2 agonists (LABA), often administered using
dry powder inhalers (DPIs), are frequently prescribed to control persistent asthma and COPD. Use of DPIs has been
associated with poor inhalation technique, which can lead to increased healthcare resource use and costs.
Methods: A model was developed to estimate the healthcare resource use and costs associated with asthma and
COPD management in people using commonly prescribed DPIs (budesonide + formoterol Turbuhaler® or
fluticasone + salmeterol Accuhaler®) over 1 year in Spain, Sweden and the United Kingdom (UK). The model
considered direct costs (inhaler acquisition costs and scheduled and unscheduled healthcare costs), indirect costs
(productive days lost), and estimated the contribution of poor inhalation technique to the burden of illness.
Results: The direct cost burden of managing asthma and COPD for people using budesonide + formoterol
Turbuhaler® or fluticasone + salmeterol Accuhaler® in 2015 was estimated at €813 million, €560 million, and €774
million for Spain, Sweden and the UK, respectively. Poor inhalation technique comprised 2.2–7.7 % of direct costs,
totalling €105 million across the three countries. When lost productivity costs were included, total expenditure
increased to €1.4 billion, €1.7 billion and €3.3 billion in Spain, Sweden and the UK, respectively, with €782 million
attributable to poor inhalation technique across the three countries. Sensitivity analyses showed that the model
results were most sensitive to changes in the proportion of patients prescribed ICS and LABA FDCs, and least
sensitive to differences in the number of antimicrobials and oral corticosteroids prescribed.
Conclusions: The cost of managing asthma and COPD using commonly prescribed DPIs is considerable. A
substantial, and avoidable, contributor to this burden is poor inhalation technique. Measures that can improve
inhalation technique with current DPIs, such as easier-to-use inhalers or better patient training, could offer benefits
to patients and healthcare providers through improving disease outcomes and lowering costs.
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Background
The burden of asthma and chronic obstructive pulmonary
disease (COPD) in Europe
Asthma and COPD are common chronic inflammatory
respiratory diseases affecting 45 and 23 million people
across Europe in 2011, respectively [1]. Respiratory dis-
eases are the third leading cause of death in the European
Union (EU) and have a considerable negative impact on
patients’ physical and psychological wellbeing [2–5], im-
posing a substantial burden on healthcare providers and
society as a whole [6].
Asthma and COPD comprise approximately 78 % of
total direct healthcare costs associated with managing
respiratory diseases in the EU, amounting to €42.8 bil-
lion in 2011 [7]. The economic burden of asthma and
COPD increases markedly when indirect costs – such as
those associated with lost productivity and carer time –
are considered. In Europe, the annual indirect costs of
asthma and COPD are approximately equal to the direct
healthcare costs, totalling €14.4 billion and €25.1 billion
in 2011, respectively [7].
Treatment of asthma and COPD
There are a broad range of options available for the
management of asthma and COPD. Controller medi-
cines, such as inhaled corticosteroids (ICS), long-acting
muscarinic antagonists (LAMA), long-acting β2 agonists
(LABA) and anti-immunoglobulin E (anti-IgE), are taken
preventatively to manage asthma and COPD – although
the effectiveness of anti-IgE has been questioned [8]. In
contrast, short-acting muscarinic antagonists (SAMA)
and short-acting β2 agonists (SABA) are used as rescue
medications to provide immediate relief from exacerba-
tions [9, 10]. For patients with persistent asthma and
COPD, global clinical guidelines recommend treatment
with a fixed-dose combination (FDC) of ICS + LABA, ei-
ther as a controller medication with as-needed SABA as
rescue medication, or as both controller and rescue
medication [9, 10].
Asthma and COPD medicines are commonly ad-
ministered using either a pressurised metered dose in-
haler (pMDI) or a dry powder inhaler (DPI) [9].
pMDIs function by user activation of a pressurised
propellant [11], requiring a degree of dexterity, skill
and training to co-ordinate actuation and inhalation
in order to deliver the correct dose [9, 12]. DPIs are
breath-actuated [11], with little hand-breath co-
ordination required, making them easier to use than
pMDIs [9, 13, 14], and are typically recommended
over pMDIs [15, 16]. Clinicians and guidelines from
international bodies recognise that the choice of
medicine and inhaler is critical for achieving success-
ful management of asthma and COPD [15–17].
Poor inhalation technique
Critical inhaler errors – defined as errors which signifi-
cantly reduce, or prevent entirely, deposition of medicine
in the lungs [18] – can be considered a measure of poor
inhalation technique. In 2011, Melani and colleagues
published results of a three-month, cross-sectional study
of 1,664 Italian asthma and COPD patients using DPIs,
which found that 44 % of people using budesonide + for-
moterol (BF) Turbuhaler® (Symbicort® Turbuhaler®) and
34 % of people using fluticasone + salmeterol (FS) Accu-
haler® (Seretide® Accuhaler®) had poor inhalation tech-
nique [19]. Moreover, a systematic review of patients
with asthma and COPD found that up to 94 % of DPI
users made at least one inhaler error when examined by
a healthcare professional (HCP) [20].
Importantly, HCPs may also demonstrate poor inhal-
ation technique. Independent studies from multiple
countries have shown that at least a third of – and in
some cases all – HCPs performed at least one critical
error with pMDIs and DPIs [21–25]. Similarly, a review
of 20 studies of pMDI and DPI use found that more
than three quarters of nurses, and over a third of re-
spiratory specialists, did not perform all stages of inhal-
ation correctly [26]. The frequency with which HCPs
can demonstrate poor inhalation technique indicates
that commonly prescribed inhalers are difficult to use.
As HCPs are charged with teaching patients to use in-
halers effectively, poor inhalation technique among
HCPs may result in patients receiving incorrect or in-
consistent advice and training.
Studies from many countries have shown that poor in-
halation technique correlates with reduced disease con-
trol and increased use of healthcare resources [16, 27],
which in turn negatively impacts patient health-related
quality of life (HRQoL) [28]. Therefore, poor inhalation
technique presents a potentially considerable, and avoid-
able, burden to healthcare organisations and patients
alike. Although it is widely accepted that inhalation tech-
nique is a significant factor in the control of respiratory
disease [29], its contribution to the cost of asthma and
COPD management has not been quantified. An eco-
nomic model was designed to assess the healthcare and
societal burden of managing asthma and COPD using
DPIs containing ICS + LABA FDCs, and how this may
be impacted by poor inhalation technique.
Methods
Model design
A burden-of-illness model was developed from a societal
perspective for Spain, Sweden and the United Kingdom
(UK). These countries were chosen in order to give a
range of population sizes, geographical locations and
economies. The model assessed the economic burden of
managing asthma and COPD using either BF Turbuhaler®
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or FS Accuhaler® over 1 year, and estimated the contribu-
tion of poor inhalation technique to this burden. These in-
halers were chosen as they are the most commonly
prescribed DPIs in Europe [30].
Direct and indirect costs were included in the model.
Direct costs included inhaler acquisition costs, scheduled
healthcare costs (visits to nurses, general practitioners
(GPs), and specialists) and unscheduled healthcare costs
(hospitalisations, emergency department (ED) visits, and
additional courses of antimicrobials or oral corticosteroids
(OCS)). Indirect costs were determined using the number
of productive days lost due to asthma or COPD. Costs for
Sweden and the UK were converted to Euro using histor-
ical exchange rates [31]. All costs were inflated to 2015
values based on healthcare-specific consumer price indices
(CPIs) [32–34], except the cost of each lost productive
day, which was inflated using national CPIs [35].
Parameters
Model population
Adult asthma or COPD patients using BF Turbuhaler® or
FS Accuhaler® were included in the analysis. This popula-
tion was estimated based on the number of individuals
aged 18 years and older with diagnosed asthma or COPD,
according to population estimates from national statistical
databases [36–38] and epidemiological data from national
regulatory bodies [39–42]. The proportion of patients
receiving FDCs of ICS + LABA to manage their asthma or
COPD was calculated based on data from national regula-
tory bodies and published studies [39–41, 43, 44]. The an-
nual number of patients receiving BF Turbuhaler® or FS
Accuhaler®, at each delivered dose strength, was estimated
using 2014 national sales data (moving annual total; a roll-
ing measure of data from the past year taken every month)
[30] (Table 1).
Inhaler acquisition costs
Costs of BF Turbuhaler® and FS Accuhaler® in Spain,
Sweden and the UK were sourced from the Ministry of
Health [45], national sales data (moving annual total)
[30] and the Monthly Index of Medical Specialities
(MIMS) [46, 47], respectively (Table 2).
Resource use and healthcare costs
Direct and indirect healthcare events and costs are dis-
played in Table 3. The majority of resource use inputs
and all costs were derived from country-specific sources,
such as national or regional registries and peer-reviewed
articles; where necessary, reasonable assumptions were
made to utilise applicable data.
Impact of poor inhalation technique
The proportion of patients demonstrating poor inhal-
ation technique with BF Turbuhaler® (43.5 %) and FS
Table 1 Model populationPlease check if "Tables 1-6 data" were presented correctly.The data in these tables are correct. We have
changed the formatting of the tables to make them easier to readPlease left align text in the left column of table 6.
Parameter Spain Sweden UK
Prevalence
Total number of individuals aged ≥18 (n) 37,860,506 [36] 7,772,932 [37] 50,909,098 [38]
Prevalence of diagnosed asthma (%) 3.5 [39] 8.0 [41] 6.1 [42]
Prevalence of diagnosed COPD (%) 2.8 [40] 7.0 [43] 1.8 [42]
Proportion of patients receiving ICS + LABA FDCs (%)
Asthma 33.4 [39] 50.0 [41] 35.5 [44]
COPD 33.7 [40] 39.7 [43] 35.5a
Proportion of patients using commonly prescribed DPIs to administer ICS + LABA FDCs (%)
BF Turbuhaler® 34.6 [30] 74.7 [59] 31.1 [30]
FS Accuhaler® 37.3 [30] 15.1 [59] 25.2 [30]
Prescription distribution of BF Turbuhaler® doses (%)
BF Turbuhaler® 80/4.5 μg 3.4 [30] 1.1 [30] 8.6 [30]
BF Turbuhaler® 160/4.5 μg 54.0 [30] 48.5 [30] 55.9 [30]
BF Turbuhaler® 320/9 μg 42.7 [30] 50.4 [30] 35.5 [30]
Prescription distribution of FS Accuhaler® doses (%)
FS Accuhaler® 100 μg 5.9 [30] 3.8 [30] 11.5 [30]
FS Accuhaler® 250 μg 40.1 [30] 50.3 [30] 25.5 [30]
FS Accuhaler® 500 μg 54.0 [30] 45.9 [30] 63.0 [30]
BF Turbuhaler® is marketed as Symbicort® Turbohaler® in the UK, and Symbicort® Turbuhaler® in Spain and Sweden; FS Accuhaler® is marketed as Seretide®
Accuhaler® in Spain and the UK, and Seretide® Diskus® in Sweden. Values are subject to rounding
aAssumed to be equal to proportion of asthma patients
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Accuhaler® (34.5 %) was based on the study by Melani
and colleagues [19]. It was assumed that the increased
risk of unscheduled healthcare events over baseline due
to poor inhalation technique reported in this Italian
study [19] was applicable to other European countries
(Table 4). We conservatively assumed that the increased
risk of lost productivity due to poor inhalation technique
was equal to the lowest risk increase reported for any
other event (ie hospitalisation).
Sensitivity analyses
One-way sensitivity analyses were performed using
upper and lower bounds based on reported values where
possible – if no data were available bounds were set at
±20 %. The following parameters were varied:
 Proportion of patients using ICS + LABA FDCs
(±10 %) – variation accounts for changes in
prescription habits
 Number of doses per day – the upper (3) and lower
(1) bounds reflect recommendations in the
Summary of Product Characteristics (SmPCs) for
each inhaler
 Cost of hospitalisation (±20 %)
 Cost of ED visits (±20 %)
Table 2 Cost per device
Parameter Spain (€) Sweden (€) UK (€)
BF Turbuhaler®
BF Turbuhaler® 80/4.5 μg 32.92 [45] 53.30 [30] 45.60 [46]
BF Turbuhaler® 160/4.5 μg 41.46 [45] 42.53 [30] 52.65 [46]
BF Turbuhaler® 320/9 μg 41.46 [45] 38.61 [30] 52.65 [46]
FS Accuhaler®
FS Accuhaler® 100 μg 29.38 [45] 25.84 [30] 24.88 [47]
FS Accuhaler® 250 μg 35.50 [45] 30.48 [30] 48.51 [47]
FS Accuhaler® 500 μg 47.90 [45] 40.12 [30] 56.38 [47]
Exchange rates used were GBP/EUR 0.74 and SEK/EUR 9.40
Table 3 Direct and indirect events and costs
Parameter Spain Sweden UK
Frequency (n) Cost per event (€)a Frequency (n) Cost per event (€)a Frequency (n) Cost per event (€)a
Annual scheduled healthcare events per person
Asthma
Nurse visits 0.76 [60] 18.99 [61] 0.68 [62] 62.08 [63] 0.85 [64–66] 31.35 [67]
GP visits 2.30 [68] 39.35 [61] 0.68 [62] 152.41 [63] 0.60 [64–66] 75.51 [67]
Specialist visits 2.21 [68] 78.70 [60] 0.34 [62] 206.25 [63] 0.15 [69]b 133.93 [67]
COPD
Nurse visits 0.76 [60] 18.99 [61] 0.00c 0.00c 1.05 [64, 66] 31.35 [67]
GP visits 0.47 [68] 39.35 [61] 1.70 [70] 152.41 [63] 1.30 [64, 66] 75.51 [67]
Specialist visits 1.43 [68] 78.70 [60] 1.70 [70] 206.25 [63] 3.42 [71] 133.93 [67]
Annual unscheduled healthcare events per person
Asthma
Hospitalisations 0.09 [60, 68] 4,495.90 [61, 68] 0.12 [62, 72]d 748.15 [63, 72]d 0.02 [72, 73] 1,753.68 [74]
ED visits 0.26 [60, 68] 181.62 [61, 68] 0.20 [75] 177.67 [63] 0.02 [72, 73] 182.12 [74]
Antimicrobial courses 0.70 [76]e 4.76 [77] 0.50f 1.07 [78] 0.70 [76]e 25.65 [79, 80]
OCS courses 0.63 [81] 17.22 [77] 0.20f 2.34 [78] 0.14 [81] 55.28 [82]
COPD
Hospitalisations 0.26 [60, 68] 3,448.13 [49, 61] 0.38 [70, 72]d 1,915.26 [63, 72]d 0.12 [72, 73] 3,554.73 [74]
ED visits 0.08 [60, 68] 181.62 [49, 61] 0.31 [43] 177.67 [63] 0.12 [72, 73] 182.12 [74]
Antimicrobial courses 0.38 [83] 4.76 [77] 2.00f 1.07 [78] 1.51 [83] 2.94 [84, 85]
OCS courses 0.17 [83] 17.22 [77] 1.60f 2.34 [78] 0.68 [83] 55.28 [82]
Annual productivity losses per person
Productive days lost (asthma) 12.00 [86, 87] 62.04 [36] 4.00 [62] 205.50 [88] 17.00 [89, 90] 169.22 [91]
Productive days lost (COPD) 24.00g 62.04 [36] 24.00g 205.50 [88] 24.00 [73, 92] 169.22 [91]
aAll cost values are inflated to May 2015 figures, and converted to Euro, where appropriate. bData reported by an American cohort study of members of a
managed care organisation [69] – assumed to be representative of the UK. cPatients with severe COPD in Sweden receive outpatient care from GPs and
specialists, and do not visit nurses (based on an interview with a clinical expert).dCalculated using average length of stay data from UK hospitals [70]. eData
reported by a study of Irish GP practices [76] – assumed to be representative of Spain and the UK. f Values based on the opinion of a clinical expert. gData
assumed to be the same as reported for the UK. Values are subject to rounding
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 Cost of additional courses of antimicrobials (±20 %)
 Cost of additional courses of OCS (±20 %)
 Proportion of patients with poor inhalation
technique (±20 %)
Results
Number of events
The annual number of events is shown in Table 5. The
largest eligible patient population was in the UK,
followed by Spain and Sweden. The number of product-
ive days lost due to asthma and COPD aligned with the
relative size of the eligible population for each country,
and comprised 83.8–93.8 % of the total number of all re-
ported events in each country.
Costs
The estimated total direct costs of asthma and COPD in
2015 were predicted to be €813 million, €560 million
and €774 million in Spain, Sweden and the UK, respect-
ively. Despite having the largest eligible population, the
costs of asthma and COPD per patient were lowest in
the UK, while the highest per-patient costs were in-
curred in Spain (Fig. 1). Inclusion of indirect costs in-
creased the burden of asthma and COPD substantially,
with the costs per-patient rising to €2,474, €3,675 and
€4,060 in Spain, Sweden and UK, respectively, resulting
in total annual costs of €1.4 billion, €1.7 billion and €3.3
billion, respectively. Despite patients in Spain losing
more productive days on average compared with pa-
tients in Sweden, total annual indirect costs in Spain
were approximately half of those for Sweden (€0.60 bil-
lion compared with €1.18 billion, respectively).
Poor inhalation technique
The contribution of poor inhalation technique to the
burden of asthma and COPD is summarised in Table 6.
Across the three countries studied, 15.4–20.7 % of un-
scheduled healthcare events and costs were attributable
to poor inhalation technique.
Figure 2 reveals that the per-patient costs of unsched-
uled healthcare events due to poor inhalation technique
were highest in Spain (€109), followed by Sweden (€55)
and the UK (€21). Per-patient costs in Spain were sub-
stantially higher than in the other two countries due to
the high costs of hospitalisation. The contribution of
additional courses of antimicrobials and OCS to the cost
burden of poor inhalation technique in Spain and
Sweden was negligible; however, in the UK, these costs
were each greater than the costs of ED visits.
The total cost burden of poor inhalation technique more
than doubled when productivity losses were taken into ac-
count (Table 6). These indirect costs were highest in the
UK (€390 million), followed by Sweden (€194 million) and
Spain (€93 million). Inclusion of indirect costs increased
Table 4 Increased risk of unscheduled healthcare events
associated with poor inhalation technique
Unscheduled healthcare event Increased riska
Hospitalisation 47 %
ED visit 62 %
Course of antimicrobials 50 %
Course of OCS 54 %
Productive day lost 47%b
aBased on the increased risk over patients with correct inhaler technique
(odds ratio) of at least one critical inhaler error and self-reported utilisation of
healthcare resources used in the year since the critical inhaler error [19]
bConservatively assumed to be equal to the lowest increased risk reported for
any unscheduled healthcare event (hospitalisation)
Table 5 Total annual number of events due to asthma and COPD
Output Spain Sweden UK
Population (adults receiving BF Turbuhaler® or FS Accuhaler®) 572,317 473,022 803,821
Number of scheduled healthcare events
Nurse visit 434,961 189,795 719,878
GP visit 854,662 519,445 610,497
Specialist visit 1,068,044 424,548 721,953
Total 2,357,668 1,133,788 2,052,328
Number of unscheduled healthcare events
Hospitalisation 92,676 106,546 33,851
ED visits 101,035 115,077 33,715
Antimicrobial courses 313,760 524,096 699,262
OCS courses 239,520 363,655 207,711
Total 746,991 1,109,374 974,539
Number of productive days lost
Lost productivity 9,895,128 5,736,196 14,712,035
Values are subject to rounding
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the total per-patient costs of poor inhalation technique to
€271 in Spain, €466 in Sweden and €506 in the UK.
Sensitivity analyses
The results of the one-way sensitivity analyses are shown
in Fig. 3. The model was most sensitive to the propor-
tion of patients using ICS + LABA, and moderately sen-
sitive to the number of doses per day and the cost per
hospitalisation. The ranking of each parameter was simi-
lar across the three countries; with regards to Spain, the
model was more sensitive to the costs of hospitalisation
than to the number of doses per day for mid-strength
inhalers, while the model in Sweden was more sensitive
to the number of doses per day for mid strength inhalers
than high strength inhalers.
Discussion
We developed a model to estimate the burden of managing
asthma and COPD with the most commonly prescribed
DPIs in Spain, Sweden and the UK. Our analysis estimated
the burden to be substantial, with 572,317, 473,022 and
803,821 adults using BF Turbuhaler® or FS Accuhaler® in
Spain, Sweden and the UK, respectively. Given the popula-
tion size differences between countries, the proportion of
adults included in the model for Sweden was high relative
to those values estimated for Spain and the UK – this was
likely due to a higher prevalence of asthma and COPD, and
higher prescription rates of BF Turbuhaler®.
A total of 5.5 million scheduled and 2.8 million un-
scheduled healthcare events were estimated to occur
across the three countries annually. The highest number
of scheduled healthcare events was estimated to occur in
Spain, primarily driven by a higher incidence of special-
ist visits compared with other countries. The highest
number of unscheduled healthcare events occurred in
Sweden, despite it having the lowest eligible patient
population among the countries studied; this may be
due to the high prescription rates of BF Turbuhaler®, as
patients using this inhaler have a higher risk of incurring
unscheduled healthcare events than patients using FS
Accuhaler® [19].
The model estimated direct per-patient costs (inhaler
acquisition costs, scheduled healthcare costs and un-
scheduled healthcare costs) of disease management in
Spain, Sweden and the UK to be €1,421, €1,183 and
€963, respectively. These values are in broad agreement
with previously published cost estimates. For example,
in 2007, a prospective observational study of 627 asthma
patients in Spain reported a direct annual cost of €1,533
per patient [48], while in 2003 a separate, multicentre,
epidemiological study of 10,711 Spanish COPD patients
determined the cost per patient to be €1,922 [49]. When
inflation is applied to these values, the reported annual
per-patient costs of asthma and COPD in Spain are
€1,675 and €2,111, respectively [32]. Minor differences
in cost estimates compared with our results are likely
due to variations in methods of data collection and ana-
lysis, treatment regimens, patient populations and dis-
ease severity, and regional healthcare costs.
In the UK, the direct cost burden of asthma and
COPD was reported to be £1.8 billion in 2012 [50],
which, when converted to Euro and inflated to 2015
values [31], equates to €2.6 billion. Our analysis esti-
mated the direct cost of managing patients using BF
Turbuhaler® or FS Accuhaler® – who represent 20 % of
the total UK asthma and COPD patient population – to
be €774 million, which is approximately 29.8 % of the re-
ported total costs for the UK. Therefore, assuming the
two studies are comparable, patients considered by our
model have higher than average costs of asthma and
COPD management, which is to be expected as these
patients have persistent forms of disease.
The model showed that the indirect costs of asthma
and COPD exceeded the direct costs in Sweden and the
Fig. 1 Annual direct per-patient costs of asthma and COPD. The annual per-patient costs of asthma and COPD were calculated by dividing the
total annual costs by the number of eligible patients in the model. Values are subject to rounding
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UK, while the two were approximately equal in Spain.
This is similar to results reported by the European Re-
spiratory Society (ERS), which stated that direct and in-
direct costs for the whole of Europe were approximately
equal [7]. Estimating the indirect costs associated with a
disease is challenging, as they are not well defined and
can be calculated in multiple ways. Whilst disability and
family carer costs add to the indirect burden of disease
[7], these costs were not included in our analysis. In-
stead, productivity losses were calculated based solely on
the number of work days lost and the average salary
within each country. Our estimation of the indirect bur-
den of asthma and COPD is therefore conservative, and
the true costs would likely eclipse those reported here.
Studies from many countries have shown that poor
inhalation technique – which is commonly observed in
users of BF Turbuhaler® and FS Accuhaler® [19] – corre-
lates with reduced disease control and increased health-
care costs [16, 27]. However, to our knowledge, no in-
depth attempt has previously been made to quantify the
Table 6 Costs of poor inhalation technique for patients using BF Turbuhaler® and FS Accuhaler®
Unscheduled healthcare events Spain Sweden UK
Frequency
(n; thousands)
Cost
(€; millions)
Frequency
(n; thousands)
Cost
(€; millions)
Frequency
(n; thousands)
Cost
(€; millions)
Hospitalisations
Total 92.7 373.9 106.5 130.7 33.9 73.3
Not due to poor inhalation technique 78.4 316.2 89.0 109.2 28.6 61.8
Due to poor inhalation techniquea 14.3 57.7 17.6 21.5 5.3 11.5
Contribution of poor inhalation techniqueb(%) 15.4 16.5 15.6
ED visits
Total 101.0 18.4 115.1 20.4 33.7 6.1
Not due to poor inhalation technique 81.4 14.8 91.3 16.2 27.1 4.9
Due to poor inhalation techniquea 19.6 3.6 23.8 4.2 6.6 1.2
Contribution of poor inhalation techniqueb(%) 19.4 20.7 19.7
Antimicrobial courses
Total 313.8 1.5 524.1 0.6 699.3 14.3
Not due to poor inhalation technique 262.7 1.3 433.2 0.5 584.0 12.0
Due to poor inhalation techniquea 51.0 0.2 90.9 0.1 115.3 2.4
Contribution of poor inhalation techniqueb(%) 16.3 17.3 16.5
OCS courses
Total 239.5 4.1 363.7 0.9 207.7 11.5
Not due to poor inhalation technique 198.0 3.4 296.4 0.7 171.2 9.5
Due to poor inhalation techniquea 41.5 0.7 67.2 0.2 36.5 2.0
Contribution of poor inhalation techniqueb(%) 17.3 18.5 17.6
Productive days lost
Total 9,714.9 602.7 5,736.2 1,178.8 14,712.0 2,489.6
Not due to poor inhalation technique 8,215.5 509.7 4,790.8 984.5 12,409.8 2,100.0
Due to poor inhalation techniquea 1,499.4 93.0 945.4 194.3 2,302.2 389.6
Contribution of poor inhalation techniqueb(%) 15.4 16.5 15.6
Overall cost burden
Total 10,461.9 1,000.6 6,845.6 1,331.4 15,686.6 2,594.8
Not due to poor inhalation technique 8,836.0 845.4 5,700.7 1,111.1 13,220.7 2,188.2
Due to poor inhalation techniquea 1,625.8 155.2 1,144.9 220.3 2,465.9 406.7
aThe number of unscheduled healthcare events associated with poor inhalation technique is based on the increased risk of each event as reported by Melani and
colleagues [19], taking account of the proportion of patients experiencing an event who have: i) good inhalation technique; ii) poor inhalation technique, but the
reason for the event is not due to poor inhalation technique; iii) poor inhalation technique, and the poor inhalation technique is the cause of the event. The cost
of poor inhalation technique was calculated by multiplying the number of events occurring per patient due to poor inhalation technique by the weighted cost of
the event.bTotal number of unscheduled healthcare events and costs. Values are subject to rounding
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contribution of poor inhalation technique to overall
healthcare costs in DPI users. Our analysis estimated the
total direct costs of poor inhalation technique to be
€105 million annually across the three countries,
amounting to 4.9 % of the total direct costs of asthma
and COPD management. When lost productivity was in-
cluded, the total costs of poor inhalation technique rose
to €782 million (12.2 %) in Spain, Sweden and the UK.
Poor inhalation technique therefore represents a sub-
stantial budgetary and societal burden.
Several studies have shown that patient inhalation tech-
nique can be improved with additional training [27, 51, 52],
however, regular check-ups are required to maintain cor-
rect inhalation technique over time [51]. Additionally,
HCPs charged with teaching patients to use inhalers cor-
rectly often demonstrate poor inhalation technique them-
selves [26]. Education of HCPs and patients is an important
step in improving the management of asthma and COPD
[53]; however, training alone is unlikely to be sufficient for
achieving optimal control [54]. Consequently, the introduc-
tion of novel, easy-to-use inhalers that have the potential to
improve patient inhalation technique will play an important
role in optimising control of respiratory diseases [54]. In-
halers that are more intuitive to use or require less dexterity
than BF Turbuhaler® or FS Accuhaler® could reduce the
likelihood of patients making critical inhaler errors [54],
which would lower the risk of unscheduled healthcare
events [19], and – provided acquisition costs of these novel
inhalers are comparable to currently prescribed DPIs –
therefore result in direct cost savings. Indeed, correct
choice of inhaler is seen as a critical factor in the manage-
ment of asthma and COPD [15–17], as increased patient
satisfaction with an inhaler is associated with improved ad-
herence to treatment and enhanced disease control [55].
Introduction of novel inhalers that address current unmet
needs could therefore reduce the patient and economic
burden associated with asthma and COPD management.
Sensitivity analyses showed that the model was most
sensitive to the proportion of patients using ICS +
LABA, and moderately sensitive to the number of doses
per day and the costs per hospitalisation; variations
among the remaining inputs had little effect on the out-
put of the model. We therefore conclude that the model
is robust. However, there are a number of limitations to
the model. Firstly, the model does not consider the fre-
quency with which patients take their medication, the
impact of patient adherence or comorbidities. Whilst
poor patient adherence is associated with increased use
of healthcare resources [56], the absence of data sup-
porting the contribution of adherence to the different
costs considered in this analysis meant that we did not
factor adherence into the model calculations. Comorbid-
ities contribute to the number of exacerbations [57] and,
subsequently, days of lost productivity [58] experienced
by patients; however, the costs of comorbidities are hard
to quantify, and were therefore not included in this ana-
lysis. This, together with the exclusion of patient adher-
ence, likely results in conservative estimates of asthma
and COPD management costs.
Secondly, visits to nurses, GPs and specialists were
based on the total number of visits per year. The model
considered all of these visits to be scheduled healthcare
events, though in actuality some of these visits would be
due to exacerbations and would therefore be classed as
unscheduled healthcare events. As such, the model may
overestimate the cost of scheduled healthcare events and
underestimate the cost of unscheduled healthcare events
and, consequently, our reported burden of poor inhal-
ation technique is likely to be conservative. Therefore,
any reduction in the number of unscheduled healthcare
Fig. 2 Annual direct per-patient costs of poor inhalation technique. Annual per-patient costs of poor inhalation technique were calculated by dividing the
total annual costs of events attributable to poor inhalation technique by the number of patients included in the model. Values are subject to rounding
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events will likely lead to greater cost savings than would
be predicted by our model.
Thirdly, the prevalence of poor inhalation technique in
the countries studied was assumed to be the same as re-
ported in Italy [19], and the increased risk of healthcare
resource use due to poor inhalation technique was as-
sumed to be the same across all countries. While practices
perceivably vary from country to country, no studies have
estimated the impact of poor inhalation technique in
Spain, Sweden or the UK. This information would help
provide a more accurate estimate of the costs of poor in-
halation technique within these countries.
Finally, this study focusses on the impact of poor in-
halation technique on unscheduled healthcare use and
productivity losses only. Reduced disease control due to
poor inhalation technique likely reduces patient HRQoL,
which is not measured in this analysis. Melani and col-
leagues reported a significant association between asthma
and COPD patients making at least one critical inhaler
error and several patient-reported outcomes, such as
Fig. 3 One-way sensitivity analyses. *Patients prescribed 320/9 μg or 500 μg inhalers, **Patients prescribed 160/4.5 μg or 250 μg inhalers,
***Patients prescribed 80/4.5 μg or 100 μg inhalers. Sensitivity analyses for a) Spain, b) Sweden and c) the UK. Parameters were varied as
described in the Methods section. Results are displayed from the greatest change to the least change for each country. Values are subject
to rounding
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limitations during everyday life, shortness of breath, use of
rescue inhaler, and sleep disturbance [19]. Applying quan-
tifiable estimates to such outcomes would emphasise fur-
ther the burden of poor inhalation technique.
Conclusions
The cost of managing asthma and COPD with DPIs is
considerable. A substantial, and avoidable, contributor
to this burden is poor inhalation technique with
currently prescribed DPIs. Measures that can improve
inhalation technique with current DPIs, such as easier-
to-use inhalers and better patient training, could offer
benefits to patients and healthcare providers through
improved disease outcomes and lowered costs.
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